Cybin (TSE:CYBN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cybin Inc., a leader in neuropsychiatry treatments, announced that their Chief Medical Officer will participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The company specializes in innovative therapies for mental health conditions, including a psilocin program for depression and a DMT program for anxiety that are advancing through clinical trials.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges